Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gastric Cancer
Study finds no survival benefit for gastric cancer patients
May 2nd, 2007
A more intensive postoperative chemotherapy regimen for high-risk gastric cancer patients did not improve their survival, according to a randomized controlled trial in the Journal of the National Cancer Institute. The five-year survival rate for gastric cancer patients who undergo radical surgery is typically between 15 and 32 percent. Efforts to improve survival with new therapies, including postoperative chemotherapy, have yet to yield statistically significant results. Stefano Cascinu, M.D, of the Universita Politecnica delle Marche in Ancona, Italy, and colleagues conducted a multi-center, randomized phase III trial of 397 high-risk gastric...
Source: Biotech Week (2007-05-02)
|
